BRPI0414893A - corpos miméticos de núcleo de articulação mimética de epo humanos, composições, métodos e usos - Google Patents

corpos miméticos de núcleo de articulação mimética de epo humanos, composições, métodos e usos

Info

Publication number
BRPI0414893A
BRPI0414893A BRPI0414893-2A BRPI0414893A BRPI0414893A BR PI0414893 A BRPI0414893 A BR PI0414893A BR PI0414893 A BRPI0414893 A BR PI0414893A BR PI0414893 A BRPI0414893 A BR PI0414893A
Authority
BR
Brazil
Prior art keywords
mimetic
methods
joint core
compositions
human epo
Prior art date
Application number
BRPI0414893-2A
Other languages
English (en)
Inventor
George A Heavner
David M Knight
John Ghrayeb
Bernard J Scallon
Thomas C Nesspor
Chichi Huang
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of BRPI0414893A publication Critical patent/BRPI0414893A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"CORPOS MIMéTICOS DE NúCLEO DE ARTICULAçãO MIMéTICA DE EPO HUMANOS, COMPOSIçõES, MéTODOS E USOS". A presente invenção refere-se a pelo menos um novo corpo mimético de núcleo de articulação mimética de EPO humano, porção específica ou variante incluindo ácidos nucléicos isolados que codificam, pelo menos, um corpo mimético de núcleo de articulação mimética de EPO, porção especificada ou variante, corpo mimético de núcleo de articulação mimética de EPO, porção específica ou variantes, vetores, células hospedeiras, animais transgênicos ou plantas e métodos para fabricação e uso dos mesmos, incluindo composições terapêuticas, métodos e dispositivos.
BRPI0414893-2A 2003-09-30 2004-09-03 corpos miméticos de núcleo de articulação mimética de epo humanos, composições, métodos e usos BRPI0414893A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50734903P 2003-09-30 2003-09-30
PCT/US2004/028976 WO2005032460A2 (en) 2003-09-30 2004-09-03 Human epo mimetic hinge core mimetibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
BRPI0414893A true BRPI0414893A (pt) 2006-11-21

Family

ID=34421611

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414893-2A BRPI0414893A (pt) 2003-09-30 2004-09-03 corpos miméticos de núcleo de articulação mimética de epo humanos, composições, métodos e usos

Country Status (28)

Country Link
EP (2) EP2123675A3 (pt)
JP (1) JP4810428B2 (pt)
KR (1) KR101201339B1 (pt)
CN (1) CN1894275B (pt)
AR (1) AR046415A1 (pt)
AT (1) ATE439370T1 (pt)
AU (1) AU2004277884B2 (pt)
BR (1) BRPI0414893A (pt)
CA (1) CA2540665A1 (pt)
CO (1) CO5690612A2 (pt)
CR (1) CR8320A (pt)
CY (1) CY1109579T1 (pt)
DE (1) DE602004022571D1 (pt)
DK (1) DK1675579T3 (pt)
EA (1) EA009377B1 (pt)
EC (1) ECSP066466A (pt)
ES (1) ES2329799T3 (pt)
IL (2) IL174676A (pt)
NO (1) NO20061931L (pt)
NZ (1) NZ546287A (pt)
PL (1) PL1675579T3 (pt)
PT (1) PT1675579E (pt)
SG (1) SG149074A1 (pt)
SI (1) SI1675579T1 (pt)
TW (1) TWI344987B (pt)
UA (1) UA89481C2 (pt)
WO (1) WO2005032460A2 (pt)
ZA (1) ZA200603425B (pt)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799700A4 (en) 2004-09-27 2009-02-11 Centocor Inc SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
EP2007602A4 (en) * 2006-03-31 2010-09-22 Centocor Ortho Biotech Inc HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY
US8536113B2 (en) 2006-12-21 2013-09-17 Janssen Biotech, Inc. EGFR binding peptides and uses thereof
WO2008079982A2 (en) 2006-12-21 2008-07-03 Centocor, Inc. Liposome composition for targeting egfr receptor
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US8278415B2 (en) 2006-12-21 2012-10-02 Centocor, Inc. Dimeric high affinity EGFR constructs and uses thereof
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
AU2009206306B2 (en) 2008-01-25 2013-06-06 Amgen Inc. Ferroportin antibodies and methods of use
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
EP2349332B1 (en) 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
EP2401302A4 (en) 2009-02-24 2013-10-09 Alexion Pharma Inc ANTIBODIES CONTAINING TPO / EPO MIMETIC THERAPEUTIC PEPTIDES
SG179131A1 (en) * 2009-09-15 2012-04-27 Kaneka Corp Modified erythropoietin to which water-soluble long-chain molecule is added
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
US8450086B2 (en) 2009-11-17 2013-05-28 Centocor Ortho Biotech Inc. Bacterial membrane protein secretion
AU2010322202B2 (en) 2009-11-17 2015-01-22 Janssen Biotech Inc. Display of disulfide linked dimeric proteins on filamentous phage
US8895700B2 (en) 2010-02-18 2014-11-25 Janssen Biotech, Inc. Monkey homolog of human interferon omega
EP2558482B1 (en) 2010-04-16 2017-09-27 Janssen Biotech, Inc. Engineered plant cysteine proteases and their uses
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
FR2964585B1 (fr) * 2010-09-15 2012-10-05 Snecma Procede et machine outil pour l'ajustage du contour d'une piece
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
JP6066356B2 (ja) * 2011-09-23 2017-01-25 ブルーバード バイオ， インコーポレイテッド 改善された遺伝子治療方法
LT3045187T (lt) 2011-10-14 2019-07-10 Amgen Inc. Injekcijų įrenginys ir surinkimo būdas
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
EP2968503B1 (en) 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin antibodies and uses thereof
TWI580451B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
CN105142695B (zh) 2013-03-15 2020-06-02 安进公司 身体轮廓可调适的自动注射器装置
SG11201507359SA (en) * 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
EP2968775B1 (en) 2013-03-15 2019-12-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
SG11201507878SA (en) 2013-03-22 2015-10-29 Amgen Inc Injector and method of assembly
EP3421066B1 (en) 2013-10-24 2021-03-03 Amgen Inc. Injector and method of assembly
EP3060281B1 (en) 2013-10-24 2019-01-30 Amgen Inc. Drug delivery system with temperature-sensitive control
HRP20250954T1 (hr) 2014-01-09 2025-10-10 Valneva Austria Gmbh Mutantni fragmenti ospa i postupci i upotrebe koji se na njih odnose
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
JP6640113B2 (ja) 2014-05-07 2020-02-05 アムジエン・インコーポレーテツド 衝撃低減要素を有する自動注入器
CN112237662B (zh) 2014-06-03 2022-10-21 安姆根有限公司 药物递送系统和使用方法
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en) 2016-05-13 2023-08-09 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
EP3592404A1 (en) 2017-03-09 2020-01-15 Amgen Inc. Insertion mechanism for drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
KR102651078B1 (ko) 2017-03-28 2024-03-22 암겐 인코포레이티드 플런저 로드 및 주사기 조립 시스템 및 방법
EP3609911B1 (en) 2017-04-13 2023-07-05 Valneva Austria GmbH Multivalent ospa polypeptides and methods and uses relating thereto
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
MA49677A (fr) 2017-07-25 2021-04-21 Amgen Inc Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
CN111132711B (zh) 2017-10-06 2022-07-01 安进公司 带有联锁组件的药物递送装置及相关组装方法
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
IL273664B1 (en) 2017-11-06 2026-02-01 Amgen Inc Full-fledged assemblies and related methods
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
EP3856284A1 (en) 2018-09-24 2021-08-04 Amgen Inc. Interventional dosing systems and methods
MA53718A (fr) 2018-09-28 2022-01-05 Amgen Inc Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
MX2021003492A (es) 2018-10-02 2021-06-18 Amgen Inc Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
AU2019359801B2 (en) 2018-10-15 2025-01-02 Amgen Inc. Platform assembly process for drug delivery device
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
MX2023013640A (es) 2021-05-21 2023-11-30 Amgen Inc Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
KR20250099137A (ko) 2022-11-02 2025-07-01 에프. 호프만-라 로슈 아게 당단백질 조성물의 생산 방법
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
DE69322789T2 (de) 1992-10-19 1999-07-01 Dura Pharmaceuticals, Inc., San Diego, Calif. Trockenpulverinhalator
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
DE69414369T2 (de) 1993-01-19 1999-05-27 Glaxo Group Ltd., Greenford, Middlesex Aerosol-spender und verfahren zu seiner herstellung
EP1978095A1 (en) 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptor proteins for controlling signal transduction and ligands binding thereto
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
NZ324374A (en) 1996-01-03 1999-06-29 Glaxo Group Ltd Inhalation device
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU2002234001B2 (en) * 2000-12-05 2008-05-01 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP1572079A4 (en) * 2002-03-29 2006-09-06 Centocor Inc MAMMAL-CDR MIMETIC BODIES, COMPOSITIONS, PROCESSES AND APPLICATION PURPOSES
CA2490409A1 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
BR0312276A (pt) * 2002-06-28 2005-04-26 Centocor Inc Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos

Also Published As

Publication number Publication date
TWI344987B (en) 2011-07-11
HK1091413A1 (en) 2007-01-19
NO20061931L (no) 2006-06-30
IL174676A0 (en) 2006-08-20
ZA200603425B (en) 2007-09-26
CN1894275A (zh) 2007-01-10
PT1675579E (pt) 2009-10-19
SG149074A1 (en) 2009-01-29
AR046415A1 (es) 2005-12-07
KR20060117930A (ko) 2006-11-17
ES2329799T3 (es) 2009-12-01
EP2123675A2 (en) 2009-11-25
NZ546287A (en) 2009-06-26
IL174676A (en) 2011-07-31
IL200117A (en) 2012-08-30
ECSP066466A (es) 2006-09-18
DK1675579T3 (da) 2009-11-02
WO2005032460A2 (en) 2005-04-14
JP2007507225A (ja) 2007-03-29
AU2004277884A1 (en) 2005-04-14
CO5690612A2 (es) 2006-10-31
KR101201339B1 (ko) 2012-11-14
AU2004277884B2 (en) 2011-04-14
EP2123675A3 (en) 2009-12-09
SI1675579T1 (sl) 2009-12-31
EA009377B1 (ru) 2007-12-28
TW200526776A (en) 2005-08-16
UA89481C2 (uk) 2010-02-10
CY1109579T1 (el) 2014-08-13
PL1675579T3 (pl) 2010-01-29
CN1894275B (zh) 2010-06-23
CA2540665A1 (en) 2005-04-14
WO2005032460A3 (en) 2006-04-13
JP4810428B2 (ja) 2011-11-09
EP1675579A2 (en) 2006-07-05
DE602004022571D1 (de) 2009-09-24
ATE439370T1 (de) 2009-08-15
EA200600525A1 (ru) 2006-08-25
CR8320A (es) 2008-09-10
EP1675579B1 (en) 2009-08-12
EP1675579A4 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
BR0312276A (pt) Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos
CR8320A (es) Mimeticuerpos humanos centrales de la region de bisagra, mimeticos de la eritropoyetina, composiciones, metodos y usos
BRPI0509528A (pt) corpos imitação de glp-1 humana, composições, processos e usos
BRPI0519241A2 (pt) agonistas, composiÇÕes, mÉtodos e usos de glp-1
BRPI0113110C8 (pt) Anticorpo anti-tnf e composição que o compreende
BR0113112A (pt) Anticorpos, de integrina antidual, composições, métodos e usos
BRPI0113109B8 (pt) anticorpo de anti-il-12 isolado, composição e método para produzir o referido anticorpo
BR0113864A (pt) ácidos nucléicos tipo kcp isolados e suas proteìnas codificadas
WO2005081687A3 (en) Human hinge core mimetibodies, compositions, methods and uses
WO2003084477A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
BRPI0410795A (pt) composições para tratamento de infecção em bovinos e suìnos
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
BR0114403A (pt) Polipeptìdeos de "haemophilus influenzae" que podem ser usados para fins de profilaxia, diagnóstico e/ou terapia
BR0112296A (pt) Composição consistindo de ou contendo pelo menos um soro de leite dissimilado
BRPI0409115A (pt) composição desodorante e/ou antiperspirante sólida macia
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
BRPI0401730A (pt) Método para controle de nematóides prejudiciais parasitas de plantas
CR9481A (es) Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos
DE60027419D1 (de) Regulatorische Sequenzen des humanen MCP-1 Gens
BR0112369A (pt) Anti-helmìnticos para evitar infecções parasitárias no homem e animal ii
FI20030379A0 (fi) Uusi farmaseuttinen koostumus
DE60038966D1 (de) Transgenes tiermodel für neurodegenerative erkrankungen
AU2002314296A1 (en) Composition for the treatment of diseases which affect animals' hooves

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.